ERBB2 and sarcoma: Eight of the 16 different cancer types had both phase II and phase III trials, including breast (HR+/HER2- high stage and triple negative high stage), colorectal, leukemia, lung, melanoma, oral cavity/pharynx and larynx, sarcoma, and stomach cancer.